Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Kidney Disease (CKD): later-stage trial registry
9 of 15 indexed Chronic Kidney Disease (CKD) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 9 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Chronic Kidney Disease (CKD): 15 US clinical trials tracked, 9 recruiting.
Chronic Kidney Disease (CKD) is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Regeneron Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition chronic-kidney-disease-ckd
OPEN 9 | RECR 60% | LATE 4 | EARLY 2 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Chronic Kidney Disease (CKD) lists 9 open slots (60% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Kidney Disease (CKD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Kidney Disease (CKD) is recruiting above its size-band peers.
9 of 15 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chronic Kidney Disease (CKD) trials is spread across many organizations.
Regeneron Pharmaceuticals accounts for 2 of 15 trials (13.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Chronic Kidney Disease (CKD) enrolment sits around 243 participants.
Median target enrolment is 243 among the 15 trials that report a genuine target (sentinel values excluded). 6 of those (40%) plan for fewer than 100 participants.
-
Chronic Kidney Disease (CKD) research is mostly interventional.
11 interventional and 4 observational studies make up this index (73.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
Clindove Research
NCT07106879
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
Duke University
NCT06906627
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Duke University
NCT06906640
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
University of Virginia
NCT06595420
Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength
VA Office of Research and Development
NCT06607913
Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
The Cleveland Clinic
NCT06694558
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
Regeneron Pharmaceuticals
NCT05092347
An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease
University of Illinois at Chicago
NCT06754280
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Regeneron Pharmaceuticals
NCT05106387
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company
NCT06383390
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Sandoz
NCT01693029
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Relypsa
NCT01810939
Virtual Nephrologist
University of Pennsylvania
NCT06841016
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
Novartis Pharmaceuticals
NCT02678000
Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
University of Florida
NCT03774394
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Kidney Disease (CKD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Kidney Disease (CKD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Kidney Disease (CKD) page
15 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Chronic Kidney Disease (CKD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Regeneron Pharmaceuticals sponsors the most Chronic Kidney Disease (CKD) trials on record, review their full trial history before evaluating a specific study. See Regeneron Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Kidney Disease (CKD) condition card totals 15 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.